The contract was signed under the assumption that Amarex would complete their 80 million dollars' worth of work in a timely fashion, at a professional standard. Their failure to do so is what makes the Leronlimab not usable in a clinical trial. An argument can be made that this delay because of Amarex's failure to fulfill its contractual agreements means that the cost of Leronlimab-- in other words, the DEBT that the company incurred -- should be paid by Amarex. They are the reason that the drug supply became useless.